Celltrion and Nippon Kayaku Strike Deal for Rituxan Biosimilar

On April 27, 2017, The Korea Herald and The Investor reported that Celltrion and Nippon Kayaku entered into an agreement under which Nippon Kayaku will sell Truxima, Celltrion’s biosimilar of Rituxan, in Japan.  According to the articles, Nippon Kayaku has exclusive rights to sell Celltrion’s Truxima, Remsima and Herzuma, and the parties will conduct clinical trials of Rituxan in Japan prior to filing for regulatory approval.